[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Children's Hospital of Eastern Ontario\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":235},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,86,112,139,162,182,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100624598","pediatric-evaluation-and-registry-for-liver-cholestasis-in-canada-100624598",false,"NCT07411716","Pediatric Evaluation and Registry for Liver Cholestasis in Canada","PEARL - Pediatric Evaluation and Registry for Liver Cholestasis in Canada","PEARL","Inclusion Criteria:\n\n* Pediatric participants (\\\u003C18 years old) with genetically confirmed or clinically diagnosed ALGS or any of the various subtypes of GIC, each associated with a distinct genetic mutation:\n\nA. PFIC Type 1 (FIC1 Deficiency) - Mutation in ATP8B1 gene. B. PFIC Type 2 (BSEP Deficiency) - Mutation in ABCB11 gene. C. PFIC Type 3 (MDR3 Deficiency) - Mutation in ABCB4 gene. D. PFIC Type 4 (TJP2 Deficiency) - Mutation in TJP2 gene. E. PFIC Type 5 (FXR Deficiency) - Mutation in NR1H4 gene. F. PFIC Type 6 (MYO5B-Associated) - Mutation in MYO5B gene. G. Progressive cholestasis of northwestern Quebec (PCNQ)-Mutation in UTP4 gene. Other novel PFIC-like conditions continue to be identified and may be included in the registry. If additional conditions are identified for inclusion in the registry, a protocol amendment will be submitted for REB approval.\n\n* Enrollment within Canadian pediatric liver centers participating in the registry. These include: Children's Hospital of Eastern Ontario (Ottawa, ON, Lead Site), CHU Sainte-Justine (Montreal, QC), McMaster Children's Hospital (Hamilton, ON), Montreal Children's Hospital (Montreal, QC), Alberta Children's Hospital (Calgary, AB), Stollery Children's Hospital (Edmonton, AB), Janeway Children's Health and Rehabilitation Centre (St. John's, NL), Jim Pattison Children's Hospital (Saskatoon, SK), Children's Hospital LHSC (London, ON), Children's Hospital IWK Health Centre (Halifax, NS), BC Children's Hospital (Vancouver, BC), HSC Winnipeg Children's Hospital (Winnipeg, MB), Hôpital de l'Enfant-Jésus (Quebec City, QC)\n* Written informed consent obtained from participant if they have the capacity, or parents\u002Fguardians, and assent from participants as appropriate.\n\nExclusion Criteria:\n\n* Inability to comply with follow-up requirements (lost to follow-up)","ALL","18 Years",{"count":20,"type":21},220,"ESTIMATED","6 Years","OBSERVATIONAL","The purpose of this study is to create a national, multi-centre registry for children with Alagille syndrome (ALGS) and Genetic Intrahepatic Cholestasis (GIC) that follows participants long-term, ensuring standardized, high-quality data capture across all participating pediatric hepatology centres.\n\nInclusion criteria:\n\n• Pediatric participants (\\\u003C18 years old) with genetically confirmed or clinically diagnosed ALGS or any of the various subtypes of GIC, each associated with a distinct genetic mutation: A. PFIC Type 1 (FIC1 Deficiency) - Mutation in ATP8B1 gene. B. PFIC Type 2 (BSEP Deficiency) - Mutation in ABCB11 gene. C. PFIC Type 3 (MDR3 Deficiency) - Mutation in ABCB4 gene. D. PFIC Type 4 (TJP2 Deficiency) - Mutation in TJP2 gene. E. PFIC Type 5 (FXR Deficiency) - Mutation in NR1H4 gene. F. PFIC Type 6 (MYO5B-Associated) - Mutation in MYO5B gene. G. Progressive cholestasis of northwestern Quebec (PCNQ)-Mutation in UTP4 gene.\n\n* Enrollment within Canadian pediatric liver centers participating in the registry.\n* Written informed consent obtained from participant if they have the capacity, or parents\u002Fguardians, and assent from participants as appropriate.\n\nExclusion criteria:\n\n• Inability to comply with follow-up requirements (lost to follow-up). Participants will be recruited from our hepatology clinics retrospectively (diagnosed on or after January 1, 2022) and prospectively (newly diagnosed). Written consent\u002Fassent will be obtained from all participants prior to data collection from the participants' medical chart.",[26,27,28],"PFIC - Progressive Familial Intrahepatic Cholestasis","Alagille Syndrome (ALGS)","Cholestasis, Intrahepatic",[30,31,32,33],"cholestasis","GIC","ALGS","PFIC","RECRUITING","2026-04-28",{"date":37,"type":38},"2026-05-04","ACTUAL",{"date":40,"type":38},"2026-04-21",{"date":42,"type":21},"2031-12",{"name":44,"class":45},"Children's Hospital of Eastern Ontario","OTHER",13,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":18,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},"100613926","mindfulness-based-intervention-for-pediatric-mild-traumatic-brain-injury-100613926","NCT07272941","Mindfulness-Based Intervention for Pediatric Mild Traumatic Brain Injury","Multisite Randomized Clinical Trial: Mindfulness-Based Intervention for Mild Traumatic Brain Injury (MBI-4-mTBI)","MBI-4-mTBI","Inclusion Criteria:\n\n* Participants presenting to five PERC EDs after sustaining a direct or indirect head injury\n* Aged 12 through 17.99 years\n* Diagnosed with a definite or suspected concussion, defined by the American College of Rehabilitation Medicine definition\n* Score ≥6 on the 5P rule\n* Suffered the index injury in the previous 48 hours\n* Proficient in English or French\n\nExclusion Criteria:\n\n* Glasgow Coma Scale ≤13\n* Abnormality on standard neuroimaging studies, including positive head CT findings (Note: neuroimaging is not required, but may be performed if clinically indicated)\n* Neurosurgical operative intervention, intubation or intensive care required\n* Multi-system injuries with treatment requiring hospital admission, operating room or procedural sedation in ED (Note: hospital admission for observation or management of ongoing concussion symptoms is not an exclusion criteria)\n* Severe neurological developmental delay resulting in communication difficulties\n* Intellectual disability\u002Fmental retardation, autism spectrum disorder (history of attention deficit hyperactivity disorder, learning disability, or Tourette's syndrome is not an exclusion)\n* Intoxication at the time of ED presentation as per clinician judgment\n* No clear history of trauma as primary events (e.g., seizure, syncope or migraine)\n* Prior psychiatric hospitalization\n* Prior diagnosis of severe psychiatric disorder such as schizophrenia (diagnosis of anxiety or depression are not exclusionary)\n* Inability to obtain a proper written informed consent\u002Fassent (language barrier, absence of parental authority, developmental delay, intoxication, patient too confused to consent, etc.)\n* Legal guardian not present (certain forms need be completed by parents\u002Flegal guardians)\n* No internet or mobile\u002Ftablet access.\n* Previously enrolled in phase 1 or phase 2 of the feasibility trial or the efficacy trial.","12 Years",{"count":57,"type":21},362,"INTERVENTIONAL",[60],"NA","Formal MBIs, such as Mindfulness-Based Stress Reduction (MBSR), have been shown to increase resiliency and teach affect regulation. However, these formal interventions may not be suitable for acutely concussed youth as they are costly, not easily accessible (trained therapists are needed), and require commitment from parents and children for in-person weekly meetings and at-home practice of learned skills for 8 to 16 weeks. Further, MBSR programs may not be readily accessible immediately after a concussion. With the increasing use of mobile phones and tablets in youth, mobile health offers a powerful platform for mental health interventions. Advantages of app-based interventions include constant availability, greater access, tailored content, lower cost, immediate delivery, and increased service capacity and efficiency. Therefore, the anticipated benefit is to show the efficacy of a pragmatic and low-cost intervention and reduce barriers to care through a novel, innovative and accessible MBI treatment program. This will have both a benefit to public health and expand our understanding of the impact of MBIs on pediatric recovery.",[63,64,65],"Concussions","Mild Traumatic Brain Injury, Concussion","Concussion Mild",[67,68,69,70,71,72,73,74,75],"mild traumatic brain injury","mtbi","concussion","intervention","meditation","quality of life","treatment","Persistent post-concussive symptoms","mindfulness","NOT_YET_RECRUITING","2026-03-17",{"date":79,"type":38},"2026-03-18",{"date":81,"type":21},"2026-05",{"date":83,"type":21},"2029-12",{"name":44,"class":45},5,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":94,"enrollmentInfo":95,"targetDuration":4,"studyType":58,"phases":97,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},"100533969","help-healthy-lifestyles-project-for-youth-with-mental-distress-100533969","NCT06232733","HELP (HEalthy Lifestyles Project) for Youth With Mental Distress","HELP (HEalthy Lifestyles Project) for Youth With Mental Distress E-Health Intervention: Patient and Healthcare Impacts","HELP","Inclusion Criteria:\n\n* Youth 12-17 years of age seeking, waiting for or receiving support for emotional distress.\n* Able to provide informed consent to study participation.\n* Able to engage in the HELP e-intervention in English (French translation of the e-modules will not be available until intervention efficacy is established).\n* Willing to be randomized to a study group.\n* Willing to complete objective behaviour measures if selected (1 of 3 participants).\n* Willing to complete the study questionnaires.\n* Willing to provide consent for evaluation of mental healthcare system outcomes via their health record.\n\nExclusion Criteria:\n\n* Identified or suspected eating disorder\n* Youth whose health or family status is deemed to be inappropriate for the study as per their most responsible clinician.","17 Years",{"count":96,"type":21},130,[60],"The goal of this clinical trial is to learn about how healthcare providers can support youths' mental health. The main question\\[s\\] it aims to answer are:\n\n* Do youth (12 to 17 years of age) who engage in the 6-month HELP e-intervention have a larger improvement in emotional health (measured by the Strengths and Difficulties Questionnaire) than youth who do not receive the intervention?\n* Does engagement in the HELP e-intervention improve lifestyle behaviour (physical activity, sleep or screen time)?\n* Do youth who engage in the 6-month HELP e-intervention utilize fewer mental healthcare resources, during and for 1 year following study participation, than youth who do not receive the intervention? Participants will receive the HELP intervention for 6 months, either immediately or after waiting 6 months from study enrollment. At 0, 3, 6, and 12 months, participants will answer a series of questionnaires to assess their emotional health and lifestyle behaviors. Researchers will compare the emotional health and lifestyle behaviors of youth who received HELP immediately to those who wait for 6 months prior to the intervention to see if their emotional health or lifestyle behaviors differ.",[100],"Mental Health Issue",[102,103],"adolescent","healthy lifestyle behavior","2026-03-16",{"date":77,"type":38},{"date":107,"type":38},"2024-06-15",{"date":109,"type":21},"2028-12-31",{"name":44,"class":45},1,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":120,"maxAge":18,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},"100577674","video-clips-for-diagnostic-evaluation-of-obstructive-sleep-apnea-in-children-100577674","NCT06801366","VIdeo Clips for Diagnostic Evaluation of Obstructive Sleep Apnea in Children","VIdeo Clips for Diagnostic Evaluation of Obstructive Sleep Apnea in Children (VIDEO)","VIDEO","Inclusion Criteria:\n\n* 2-18 years old\n* referred for diagnostic PSG to assess for OSA at their local tertiary care centre\n* parent\u002Fcaregiver has access to mobile technology\n\nExclusion Criteria:\n\n* previous diagnosis of sleep-disordered breathing based on PSG in the last five years\n* unable to cooperate for PSG\n* clinician-suspected presence of central sleep apnea or central hypoventilation\n* genetic or congenital syndrome\n* non-verbal\n* use of PAP therapy or tracheostomy\n* parent\u002Fcaregiver does not speak English or French","2 Years",{"count":122,"type":21},625,"Obstructive sleep apnea (OSA), which occurs in 1-4% of children, is a serious condition where a person stops breathing periodically during sleep because their airway closes. Untreated, it is associated with high blood pressure, behavioural problems, and lower quality of life. While early diagnosis and treatment are critical, there are significant barriers to access to a sleep study (the best diagnostic test). Questionnaires and overnight oxygen level recordings are limited in their ability to identify OSA. Better screening tools are needed to identify and prioritize children for sleep study testing. Short video clips, recorded using smartphones by parents, may be a useful tool to identify children at risk of OSA who would most benefit from a sleep study. The study aims to evaluate the ability of home smartphone video clips as a screening tool for moderate-severe OSA in children referred for a sleep study. The utility of video clips will also be compared to questionnaires and overnight oxygen saturation recordings. The investigators believe that the video clips will be able to predict moderate-severe OSA in children and that they will be better than standard clinical questionnaires or oxygen recordings. This multi-centre study will include 625 children referred for sleep studies for suspected OSA. Parents will be asked to record short video clips of their child sleeping, which will be rated for the presence and severity of OSA. Children will then undergo a sleep study, and parents will complete a questionnaire about sleep symptoms. Oxygen level recordings will be extracted from the sleep study. The diagnostic accuracy of video clips will be determined and compared to the questionnaire and oxygen level recording. This new approach to screening for pediatric OSA using widely available technology will allow children at the highest risk for moderate-severe OSA to be diagnosed and treated earlier, minimizing the risk of long-term complications.",[125],"Obstructive Sleep Apnea (OSA)",[127,128,129],"obstructive sleep apnea","polysomnography","videos","2026-01-05",{"date":132,"type":38},"2026-01-07",{"date":134,"type":38},"2025-03-18",{"date":136,"type":21},"2029-07-01",{"name":44,"class":45},4,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":146,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":138},"100521101","early-life-mri-biomarkers-of-longer-term-respiratory-morbidity-in-infants-born-extremely-preterm-emblem-100521101","NCT06065215","Early-life MRI Biomarkers of Longer-term Respiratory Morbidity in Infants Born Extremely Preterm (EMBLEM)","EMBLEM","Inclusion Criteria:\n\n1. Infants born at \\\u003C29 weeks gestation;\n2. currently \\\u003C36 weeks PMA.\n\nExclusion Criteria:\n\n1. Known interstitial lung disease, congenital lung anomaly, ciliary dysfunction, immunodeficiency, cystic fibrosis, neuromuscular disease, or structural heart disease (other than atrial septal defect\u002Fhemodynamically insignificant ventricular septal defect\u002Fpatent ductus arteriosus);\n2. genetic syndrome or congenital anomaly;\n3. contraindications for MRI or transport;\n4. invasive or non-invasive ventilation that cannot be safely removed for MRI;\n5. current respiratory infection;\n6. family cannot speak English\u002FFrench;\n7. transferred to another hospital prior to baseline study visit\n8. not receiving follow-up at one of the study centres.","35 Weeks","21 Months",{"count":149,"type":21},319,"Bronchopulmonary dysplasia (BPD) is a common, major complication of premature birth, associated with developmental and health consequences that continue into adulthood. Prediction of who will have these problems is challenging using traditional definitions of disease. It is believed that underdevelopment and injury occur in both lung tissue and the blood vessels in the lungs, with a sophisticated interplay between them that contributes to lung disease seen in prematurity. New magnetic resonance imaging (MRI) techniques can delineate tissue structure with unprecedented granularity, assessing lung tissue, blood vessels, and their interplay. The ability to identify, at an early stage, those infants destined for chronic lung disease with greater certainty will be useful in counseling families and critical for the effective introduction of promising new BPD therapies. 319 infants born less than 29 weeks gestation will be recruited from 4 centres, including 5 babies who received stem cell therapy in a clinical trial. Babies will be evaluated at 36 weeks post-conception with lung MRI, oscillometry (lung function), echocardiogram (heart ultrasound), and oscillometry. Lung health will be assessed every 3 months by phone questionnaire and chart review. At 18-21 months post-conception, babies will undergo neurodevelopmental assessment and lung function testing. The investigators will look at how well baseline MRI markers predict subsequent lung health and development, independently and combined with echocardiogram, lung ultrasound, and traditional markers of BPD. The investigators anticipate that these new MRI markers will measure lung health safely and longitudinally in babies born extremely preterm. By identifying predictors of longer-term lung disease, clinicians will be able to allocate resources to babies at the highest risk of severe disease. Further, The investigators envision that MRI will help identify babies who would benefit most from interventions like stem cell therapy and be useful for evaluation of future treatments.",[152,153],"Lung Function","BPD - Bronchopulmonary Dysplasia","2025-02-21",{"date":156,"type":38},"2025-02-24",{"date":158,"type":38},"2024-03-30",{"date":160,"type":21},"2027-06-30",{"name":44,"class":45},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":111},"100549816","msot-as-non-invasive-biomarker-for-diagnosis-and-monitoring-of-neuromuscular-diseases-100549816","NCT06438965","MSOT as Non-invasive Biomarker for Diagnosis and Monitoring of Neuromuscular Diseases","Multispectral Optoacoustic Imaging (MSOT) as Non-invasive Biomarker for Diagnosis and Monitoring of Neuromuscular Diseases (MSOT-NMD)","Inclusion Criteria:\n\nPatients with neuromuscular disease\n\n* Children (from birth (infants that are born term) to 18 years of age) participants or consent through authorized guardian\n* Confirmed or suspected diagnosis of a neuromuscular disease (through molecular genetics, biopsy, clinical examination)\n\nExclusion Criteria:\n\nParticipants:\n\n* Diagnosis is not consistent with a confirmed or suspected neuromuscular disease\n* Patients with active skin lesions (e.g. infections, trauma) or confirmed genetic disorders (e.g. epidermolysis bullosa) that predisposes to skin lesion\n* Medically unstable patients\n* Tattoo on skin overlying the area to be examined\n* Missing consent form\n* Exclusion due to safety concerns of the investigator (subject who has any condition, including any physical, psychological, or psychiatric condition, which in the opinion of the Investigator, would compromise the safety of the subject or the quality of the data and renders the subject an unsuitable candidate for the study)\n* Medication leading to increased light sensitivity",{"count":170,"type":21},240,"The goal of this study is to learn if Multispectral Optoacoustic Tomographs (MSOT) works to diagnose and follow the course of neuromuscular diseases (NMDs) in children. MSOT scans will be obtained from muscle region to measure hemo\u002Fmyoglobin, collagen and lipid content\u002Fsignal and oxygenation in patients with neuromuscular diseases. No additional research activities -other than MSOT - will be done during this study. Existing clinical, laboratory and imaging data from standard-of-care procedures will be correlated with the MSOT data. The expected total duration of the study is approximately 36 months. Repeated measurements will be done to evaluate disease progression and the value of MSOT in NMD.",[173],"Neuromuscular Diseases","2025-02-10",{"date":176,"type":38},"2025-02-12",{"date":178,"type":38},"2025-02-07",{"date":180,"type":21},"2028-07",{"name":44,"class":45},{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":94,"enrollmentInfo":190,"targetDuration":4,"studyType":58,"phases":192,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":111},"100544242","study-of-iv-ketamine-for-emergency-department-treatment-of-adolescent-suicidal-ideation-100544242","NCT06366334","Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation","A Double Blinded, Randomized, Placebo Controlled, Parallel Arm Pilot Trial of Intravenous Ketamine for Emergency Department Treatment of Suicidal Ideation in a Pediatric Population.","KSI","Inclusion Criteria:\n\n1. Responds \"yes\" to Ask Suicide Screening Question (ASQ) #5 at triage, which asks; \"Are you having thoughts of killing yourself right now?\"\n2. Moderate to severe suicidal ideation, defined as score ≥ 3 on the first 5 questions of the Beck Scale for Suicidal Ideation (SSI5)\n3. Age 12 to 17 years, inclusive\n4. Medically clear (deemed fit for participation in the trial), as judged by the treating physician. Minimum criteria required to be deemed medically clear are: a) No evidence of serious physical injury requiring urgent intervention b) No evidence of acute ingestion requiring monitoring, blood tests, imaging or ECG or in the context of acute ingestion they have satisfied the requisite number of hours of post-ingestion monitoring with no further need for intervention.\n\nExclusion Criteria:\n\n1. Acute intoxication from any substance, including alcohol\n2. Previously enrolled in the current study or currently enrolled in another clinical trial\n3. History of intellectual disability or autism spectrum disorder by patient\u002Fparent report\n4. Active, or history of, psychosis or psychotic disorder\n5. History of non-psychiatric neurologic disorder (e.g., epilepsy)\n6. Any of the following contraindications to ketamine based on the drug monograph: a) Known allergy or hypersensitivity to ketamine by patient history b) History of cerebrovascular accident (stroke or aneurysm) c) History of elevated intracranial pressure or idiopathic intracranial hypertension d) Significant hypertension requiring daily medication e) Severe cardiac decompensation\n7. On an involuntary psychiatric hold\n8. Requires physical or chemical restraint\n9. History of violence while in hospital\n10. Pregnant or breastfeeding\n11. Received opioids in the 2-hours prior to study screening",{"count":191,"type":21},20,[60],"Approximately 20% of Canadian adolescents experience thoughts of suicide, or suicidal ideation (SI), and suicide is the second leading cause of death among Canadians aged 15-19 years. The emergency department at CHEO sees approximately four patients per day with SI. Even though this is a medical emergency, there are no fast-acting treatments available.\n\nKetamine is a medication that is commonly used to safely sedate children who require painful procedures in the emergency department. For nearly ten years, intravenous ketamine has also been shown to rapidly reduce SI in adults. However, ketamine as a treatment for SI has never been studied in adolescents. The primary study objective is to pilot a clinical trial that investigates intravenous ketamine to emergently treat SI in adolescents.\n\nIf intravenous ketamine can relieve symptoms of SI for youth, this would have tremendous effects on patients and would dramatically change how physicians treat adolescent mental health emergencies. If ketamine is effective for several weeks, as it is in adults, it will help temporize patients until they receive more long-term psychiatric care. At the system level, it has the potential to reduce emergency visits and lengthy admissions. The investigators feel that the results of this study will be generalizable to pediatric centres across Canada and beyond.",[195,196],"Suicidal Ideation","Suicidal Ideas","2024-06-04",{"date":199,"type":38},"2024-06-05",{"date":201,"type":38},"2024-01-15",{"date":203,"type":21},"2024-06-28",{"name":44,"class":45},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":120,"maxAge":55,"enrollmentInfo":211,"targetDuration":4,"studyType":58,"phases":213,"briefSummary":215,"conditions":216,"keywords":218,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":111},"100159142","phase-2-celecoxib-plasma-and-cerebral-spinal-fluid-pharmacokinetics-in-children-100159142","NCT01344200","CELECOXIB Plasma and Cerebral Spinal Fluid Pharmacokinetics in Children","Inclusion Criteria:\n\nChildren aged 2-12 years, undergoing Maintenance phase chemotherapy for hematological malignancies and lymphomas (i.e. acute lymphoblastic leukemia \\[ALL\\] and lymphoblastic lymphomas \\[LLy\\] at CHEO. At this point, all patients would have achieved remission an average of 6 months earlier.\n\nExclusion Criteria:\n\n1. Age \\\u003C 2yrs and \\>12yrs old\n2. Children with non-hematologic malignancies\n3. AML\n4. Children undergoing a bone marrow aspiration (BMA) only\n5. Serum creatinine \\> 2 X UNL (upper normal limit) within 30 days\n6. Abnormal liver function; alanine aminotransferase (ALT) \\> 2 X UNL, Aspartate aminotransferase (AST) \\> 2 X UNL, total \\& direct bilirubin \\> 2 X UNL within 30 days\n7. History of peptic ulcer disease\n8. Allergy to celecoxib or NSAIDs (note: sulpha allergy does not exclude celecoxib)\n9. Recent (within 7 days) celecoxib ingestion\n10. Patients receiving CYP2C9 inhibitors fluconazole, amiodarone, oxandrolone\n11. Patients receiving CYP2C9 inducers rifampin and phenobarbitol\n12. Patients receiving high (≥ 5 gm\u002Fm2) and\u002F or escalating doses of methotrexate.\n13. Extremes of body mass index (BMI) (BMI \\\u003C5th percentile or \\>95th percentile)\n14. Parents of any participants, irrespective of age, who are unable to read and understand instructions relayed in English or French\n15. Participant and\u002For parents of any participants, irrespective of age, who suffer from dementia, psychosis or any impairment that would prohibit the understanding and giving of informed consent or study-related reporting\n16. Patient enrolled in another trial\n17. Pregnancy.",{"count":212,"type":21},65,[214],"PHASE2","Celecoxib is effective for reducing postoperative pain in adults. Children use celecoxib more rapidly than adults and require higher doses. Celecoxib is partially metabolized in the liver by a certain enzyme. A person's genetic variation of this enzyme can influence how well their body uses Celecoxib. Furthermore, Celecoxib down-regulates P-glycoprotein (P-gp), a drug efflux transporter located at the blood brain barrier responsible for central nervous system (CNS) extrusion of ondansetron and possibly fentanyl; therefore celecoxib may augment the CNS effects of these drugs.\n\nUnderstanding the blood and cerebrospinal fluid (CSF) profile of celecoxib in children and the influence of genetics on metabolism would help to develop appropriate celecoxib dosing in children for various treatment options.",[217],"Pharmacokinetics of Celecoxib in Children",[219,220,221,222,223,224,225,226],"Pharmacokinetics","Celecoxib","Children","Pharmacogenetic","ABCB1 genotype","CYP2C9 genotype","CSF","Plasma","2024-02-07",{"date":229,"type":38},"2024-02-08",{"date":231,"type":38},"2024-01-29",{"date":233,"type":21},"2027-02-01",{"name":44,"class":45},""]